ARTICLE | Clinical News
Tyrima: Phase I data
January 21, 2008 8:00 AM UTC
Data from the company’s Phase I program, which included acute dosing, repeat dosing and fed-fasted studies, showed that Tyrima was well-tolerated and had good pharmacokinetics. Doses of 10-40 mg were ...